Laboratory and Clinical Evaluation for Polycystic Ovary Syndrome (PCOS)

Mandatory Exclusion Tests

The clinical guideline recommends measuring serum thyroid‑stimulating hormone, serum prolactin, and an early‑morning 17‑hydroxyprogesterone level to exclude thyroid disease, hyperprolactinemia, and non‑classic congenital adrenal hyperplasia before confirming PCOS. 2
Non‑classic congenital adrenal hyperplasia is identified in approximately 1.5 %–6.8 % of individuals presenting with androgen excess; an early‑morning 17‑hydroxyprogesterone above the screening threshold should be followed by an ACTH stimulation test, and a stimulated level exceeding the diagnostic threshold confirms the disorder. 1

Total testosterone should be measured in a specialized reference laboratory because routine assays lack accuracy in the female range. 1
A markedly elevated serum testosterone level warrants immediate pelvic ultrasound and adrenal computed tomography to exclude an androgen‑secreting tumor. 1
Free or bioavailable testosterone is more sensitive than total testosterone for detecting hyperandrogenism. 3
Sex hormone‑binding globulin is used to calculate the free androgen index (total testosterone ÷ SHBG × 100). 1
DHEA‑sulfate measurement helps evaluate adrenal contribution to androgen excess and to rule out an adrenal source. 3

A 75‑gram oral glucose tolerance test with fasting and 2‑hour glucose measurements is required at diagnosis. 2
The OGTT should be repeated every 3–5 years, or sooner if central adiposity, rapid weight gain, or diabetic symptoms develop. 2
When OGTT is not feasible, hemoglobin A1c may be used as a substitute, acknowledging its lower sensitivity for impaired glucose tolerance. 2
A fasting lipid panel (total cholesterol, HDL, LDL, triglycerides) is obtained at diagnosis and periodically thereafter. 2
PCOS‑associated dyslipidemia—characterized by low HDL, elevated triglycerides, and small dense LDL—occurs independent of obesity. 1

Anti‑Müllerian hormone can support the PCOS diagnosis when normal or elevated and may replace ultrasound in adult patients, but it should not be used diagnostically in adolescents. 3
Mid‑luteal progesterone measurement (day 21 of a 28‑day cycle) documents ovulation in women with apparently regular cycles but suspected anovulation; spontaneous ovulation occurs in only about one‑third of such cycles. 3
A pregnancy test (β‑hCG) must be performed before initiating any hormonal therapy in women presenting with amenorrhea. 1

Body mass index and waist circumference should be recorded at every visit. 2
Blood pressure measurement is required at every visit. 2
In overweight or obese patients, screening for obstructive sleep apnea symptoms is advised, with polysomnography confirmation if screening is positive. 2

All women and adolescents with PCOS should be screened through history for depression, anxiety, eating disorders, and psychosexual dysfunction. 2
The 2023 International PCOS Guideline recommends using validated screening and assessment tools for mental health evaluation. 2

Pelvic ultrasound and adrenal CT are indicated when serum testosterone is markedly elevated. 1
Pituitary magnetic resonance imaging is advised if clinical suspicion of central hypogonadotropic hypogonadism persists (e.g., very low gonadotropins, neurological signs). 3
Free thyroxine measurement is recommended when TSH is normal but central hypothyroidism is suspected. 3
Screening for Cushing’s syndrome (24‑hour urinary free cortisol, late‑night salivary cortisol, or low‑dose dexamethasone suppression test) is indicated in women with amenorrhea, virilization, proximal muscle weakness, or frontal bossing. 1
Serum IGF‑1 measurement helps exclude acromegaly when atypical clinical features are present. 1

In adolescents, ovarian morphology and AMH levels should not be used diagnostically; diagnosis requires clinical or biochemical hyperandrogenism plus persistent oligomenorrhea lasting more than two years after menarche. 1
In perimenopausal/menopausal women, diagnosis relies on a documented long‑term history of oligomenorrhea and hyperandrogenism during reproductive years, recognizing that current menstrual symptoms have reduced specificity. 1

LH and FSH measurements are no longer required for PCOS diagnosis.
GnRH stimulation testing is reserved only for differentiating functional hypothalamic amenorrhea from organic central hypogonadism. 3
Routine endometrial cancer screening is not recommended; transvaginal ultrasound is performed only if abnormal uterine bleeding, spotting, or prolonged amenorrhea (> 90 days) occurs. 2
Routine screening for non‑alcoholic fatty liver disease is not currently advised. 2
Serum homocysteine testing is not recommended due to poor‑quality evidence. 2

Do not diagnose PCOS in adolescents based solely on polycystic ovarian morphology or elevated AMH. 1
Do not rely on routine laboratory testosterone assays; use specialized reference laboratories for accurate measurement in females. 1
Do not assume dyslipidemia is solely attributable to obesity; lipid abnormalities can occur independently of body weight in PCOS. 1
Do not postpone metabolic screening in young women, as type 2 diabetes and dyslipidemia can begin early. 1
Do not dismiss mild hyperandrogenic symptoms in adolescents; any oligomenorrhea persisting beyond two years post‑menarche combined with hyperandrogenism warrants comprehensive evaluation. 1